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preserved ratio impaired spirometry (PRISm) in
COPDGene
Emily S Wan1,2*, Peter J Castaldi1, Michael H Cho1,2, John E Hokanson3, Elizabeth A Regan4, Barry J Make4,
Terri H Beaty5, MeiLan K Han6, Jeffrey L Curtis7, Douglas Curran-Everett8,9, David A Lynch4, Dawn L DeMeo1,2,
James D Crapo4, Edwin K Silverman1,2 and The COPDGene InvestigatorsAbstract
Background: Preserved Ratio Impaired Spirometry (PRISm), defined as a reduced FEV1 in the setting of a preserved
FEV1/FVC ratio, is highly prevalent and is associated with increased respiratory symptoms, systemic inflammation,
and mortality. Studies investigating quantitative chest tomographic features, genetic associations, and subtypes in
PRISm subjects have not been reported.
Methods: Data from current and former smokers enrolled in COPDGene (n = 10,192), an observational, cross-sectional
study which recruited subjects aged 45–80 with ≥10 pack years of smoking, were analyzed. To identify epidemiological
and radiographic predictors of PRISm, we performed univariate and multivariate analyses comparing PRISm subjects
both to control subjects with normal spirometry and to subjects with COPD. To investigate common genetic predictors
of PRISm, we performed a genome-wide association study (GWAS). To explore potential subgroups within PRISm, we
performed unsupervised k-means clustering.
Results: The prevalence of PRISm in COPDGene is 12.3%. Increased dyspnea, reduced 6-minute walk distance, increased
percent emphysema and decreased total lung capacity, as well as increased segmental bronchial wall area percentage
were significant predictors (p-value <0.05) of PRISm status when compared to control subjects in multivariate models.
Although no common genetic variants were identified on GWAS testing, a significant association with Klinefelter’s
syndrome (47XXY) was observed (p-value < 0.001). Subgroups identified through k-means clustering include a
putative “COPD-subtype”, “Restrictive-subtype”, and a highly symptomatic “Metabolic-subtype”.
Conclusions: PRISm subjects are clinically and genetically heterogeneous. Future investigations into the
pathophysiological mechanisms behind and potential treatment options for subgroups within PRISm are warranted.
Trial registration: Clinicaltrials.gov Identifier: NCT000608764.
Keywords: Spirometry, Restriction, Lung diseases, SmokingBackground
Since its inception in the mid-19th century [1], spirom-
etry has become an accepted tool in the diagnosis and
staging of obstructive lung diseases (defined as the dis-
proportionate reduction in the forced expiratory volume
in the first second (FEV1) relative to the forced vital* Correspondence: emily.wan@channing.harvard.edu
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unless otherwise stated.capacity (FVC)). However, subjects with substantial, pro-
portionate impairments in FEV1 and FVC resulting in a
preserved FEV1/FVC ratio have remained a relatively
understudied group. Approximately 1 out of every 8
subjects in the general population has Preserved Ratio
Impaired Spirometry (PRISm); this pattern has alterna-
tively been referred to as “unclassified”, “non-specific”,
or “restrictive” spirometry, with the latter term being the
most widely accepted. It should be noted, however, that
the predictive value of “restrictive spirometry” for true
restriction, as defined by a reduced total lung capacity, isd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ciated with interstitial lung diseases, many PRISm subjects
do not have evidence for interstitial lung diseases on radio-
graphic evaluation [5]. Less commonly used terms, such as
”non-specific” [6] or “unclassified” spirometry [7,8], do not
make inferences regarding the etiology of the spirometric
abnormalities, but are generally uninformative.
The cross-sectional prevalence of PRISm has been esti-
mated to be between 6.6%-17.6% [9–16] worldwide. While
local and regional variability in the prevalence of PRISm ex-
ists [13,15], these estimates remain stable regardless of
whether the Global Initiative for Obstructive Lung Disease
[17] (GOLD) or lower limits of normal (LLN) diagnostic
criteria are utilized [8,14,16]. Subjects with PRISm
have increased morbidity [8–10,12,15,16,18] and mortality
[6,9,16,18]. They report increased respiratory symptoms
[9,16,19], decreased exercise capacity [12,19], more difficulty
with the activities of daily living [12,15], and have evidence
of increased systemic inflammation [20]. Additional trends
which have emerged include associations between PRISm
and increased body mass index (BMI) [6,9,10,15], diabetes
mellitus [8,12,13,18,21], cardiovascular disease [9,13,18,22],
and cigarette smoke exposure [6,10,13,15,18]. While these
summary statistics among all PRISm subjects are useful,
they fail to capture the significant heterogeneity present
within this group; for example, while the mean BMI of this
cohort is typically higher than that of the general population,
the range of BMI observed can include frankly cachectic
subjects [8,10,12,13,15,18]. In our previous analysis of
PRISm subjects among the first 2,500 subjects from COPD-
Gene [8], we hypothesized that this heterogeneity reflected
the multitude of potential underlying causes for this spiro-
metric pattern. Using data from current and former smokers
enrolled in the full COPDGene cohort, we now seek to
examine the following hypotheses:
Aim 1: We hypothesize that a distinct set of predictors
are associated with PRISm status and examine the
epidemiological, functional, and radiographic predictors
of PRISm status relative to control and COPD subjects.
Aim 2: We hypothesize that genetic variants may
contribute to the development of PRISm among
current and former smokers and explore the
associations between common genetic variants and
PRISm status relative to control subjects.
Aim 3: We hypothesize that subgroups exist within the
PRISm cohort and explore the utility of unbiased
machine learning approaches in identifying potentially
pathobiologically distinct groups within PRISm.
Materials and methods
Study population
All subjects were participants in COPDGene (ClinicalTrials.
gov Identifier NCT000608764); enrollment and exclusioncriteria have been previously described [23]. COPDGene is
a cross-sectional, observational study which enrolled
self-identified non-Hispanic white (NHW) or African
American (AA) current or former smokers aged 45–80
years with ≥10 pack-years of smoking. Institutional re-
view board approval was obtained at each of the 21
participating clinical centers (please see Additional file 1–
Additional Methods section for the names of the ap-
proving IRB offices); all subjects provided written in-
formed consent. Subjects completed questionnaires,
pre- and post-bronchodilator spirometry, 6-minute walk
test, and volumetric chest computed tomography (CT) at
full inspiration and expiration. All analyses were con-
ducted using the COPDGene phenotype dataset released
September 19, 2012.Variable definitions
Percent predicted values and lower limits of normal
(LLN) were calculated using post-bronchodilator spiro-
metric values [24]. Fixed threshold-defined groups were
as follows: PRISm subjects had an FEV1 < 80% predicted
with an FEV1/FVC ≥ 0.7, control subjects had an FEV1 ≥
80% with an FEV1/FVC ≥ 0.7, and COPD subjects had
an FEV1 < 80% predicted with an FEV1/FVC < 0.7. The
distribution of spirometry by FEV1 and FEV1/FVC in the
COPDGene cohort is illustrated in Figure 1. LLN-defined
cohorts were defined as follows: LLN-PRISm subjects had
FEV1 < LLN with an FEV1/FVC ≥ LLN, LLN-controls had
FEV1 ≥ LLN with an FEV1/FVC ≥ LLN, while LLN-COPD
subjects had FEV1 < LLN and FEV1/FVC < LLN. The dis-
tribution of spirometry and delineation of LLN-defined
populations are illustrated in Additional file 1: Figure S1.
Additional variable definitions are available in detail (see
Additional file 1).Aim 1: Epidemiological analysis
Univariate comparisons between PRISm subjects and
control or COPD subjects were made using a Student’s
t-test or Wilcoxon rank sum test for normal and non-
normally distributed continuous variables, respectively,
while Chi-square or Fisher’s exact tests were used for
discrete variables. All nominally significant variables
(punivariate < 0.05), except lung function and medication
use variables, were considered candidate independent
variables for multivariate regression. Logistic regres-
sion using automated stepwise selection with binary
PRISm status as the dependent variable was performed
using SAS (v 9.3, Cary, NC); a significance level of 0.1
was specified for entry into the model and independent
variables with a p-value <0.05 were retained in the final
model. Additional details regarding stepwise selection
are outlined in the Additional file 1 – Methods section.
Non-significant candidate independent variables were
Figure 1 Distribution of spirometry in COPDGene. Legend: Forced expiratory volume in the first second (FEV1) is plotted on the x-axis while
FEV1/FVC ratio is plotted on the y-axis. Dashed lines represent fixed-threshold criteria used to delineate Preserved Ratio Impaired Spirometry
(PRISm) subjects (highlighted in blue-upper left quadrant), control (upper right quadrant), and COPD (lower left quadrant) subjects.
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in the effect estimate was observed.
Aim 2: Genetic analysis
Genome-wide single nucleotide polymorphism (SNP)
genotyping data were obtained on the Illumina (San
Diego, CA, USA) OmniExpress platform with additional
genotypes imputed using MaCH [25] software and
the 1000 Genomes [26] phased data (Hg19) for a total
of ~14.9 million SNPs. Additional details regarding
data processing and quality control are available (see
Additional file 1). Genome-wide association testing for
associations with binary PRISm status relative to control
subjects was performed using an additive model, adjusted
for age, sex, pack-years of smoking, BMI, current smoking
status and principal components for genetic ancestry.
Analyses were performed separately in non-Hispanic
white and African American subjects using PLINK [27];
meta-analysis using standard error weighting was then
performed using METAL software [28].
Aim 3: Unsupervised cluster analysis to identify potential
subgroups within PRISm
Unsupervised k-means clustering analyses were con-
ducted on the subset of PRISm subjects (nfixed threshold =
1,135 and nLLN = 978) with complete data for six empir-
ically chosen key input variables: TLCCT% predicted,
FEV1% predicted, FEV1/FVC ratio, percent emphysema(%LAA-950insp), BMI, and segmental wall area percent.
Normalized mutual information (NMI) using a five-fold
cross-validation strategy was used to determine the opti-
mal number of clusters [29]. To assess whether differ-
ences in the number or types of subgroups identified
differed by race and to reduce the impact of population
stratification, clustering and candidate gene testing were
performed separately in NHW and AA subjects using R
(2.15.0) [30]. Additional details regarding the cluster
analysis are available in the Additional file 1.
Results
Aim 1: Epidemiological, functional, and radiographic
predictors of PRISm status
Among the current and former smokers enrolled in the
COPDGene cohort (n = 10,192), the mean age was
59.6 years, the mean pack-years smoked was 44.2, and
mean body mass index (BMI) was 28.8; 53.5% of the
cohort was male, 33.4% were African American, and
53.1% were current smokers. By fixed-threshold cri-
teria, PRISm subjects account for 12.3% (n = 1,257) of
the COPDGene cohort (Figure 1). Univariate compari-
sons between PRISm subjects and 1) control subjects
and 2) COPD subjects are summarized in Table 1.
PRISm subjects have the highest proportion of females
and current smokers, increased mean body mass index
(BMI) and decreased mean total lung capacity, as well
as an increased prevalence of diabetes mellitus relative
Table 1 Characteristics of Preserved Ratio Impaired Spirometry (PRISm), smoking control, and COPD subjects in
COPDGene using fixed threshold criteria
Control subjects PRISm COPD
n 4388 1257 3690
Age 56.7 (8.4)* 57.2 (8.2) 63.4 (8.5)*
Sex (% Male) 52.9* 46.1 55.6*
African American 41.2 43.1 22.7*
Current smoker 59.7* 63.8 40.7*
Pack-years 37.2 (20.2)* 42.7 (24.2) 53.0 (27.5)*
Body Mass Index 28.9 (5.8)* 31.8 (7.3) 28.1 (6.3)*
FEV1% predicted 97.5 (11.5)* 70.2 (8.4) 50.2 (18.0)*
FVC% predicted 96.6 (11.9)* 71.5 (9.1) 76.3 (17.3)*
FEV1/FVC 0.79 (0.05)* 0.77 (0.05) 0.50 (0.13)*
Bronchodilator Responsiveness† 10.0* 13.7 36.6*
Total Lung CapacityCT% predicted 92.3 (14.6)* 79.9 (13.5) 101.5 (17.1)*
Segmental wall area percentage 60.1 (2.9)* 62.5 (3.1) 62.9 (3.1)*
Percent emphysema (% LAA-950insp) 2.0 (2.5)* 1.4 (2.5) 13.0 (12.8)*
Percent gas trapping (% LAA-856exp) 11.0 (9.7) 10.4 (9.1) 39.2 (20.8)*
Pi10 3.65 (0.11)* 3.73 (0.14) 3.72 (0.14)*
6 minute walk distance (feet) 1491.5 (350.7)* 1266.6 (366.9) 1174.8 (397.0)*
MMRC‡ Dyspnea score 0.8 (1.2)* 1.5 (1.5) 2.1 (1.4)*
Resting O2 saturation 97.1 (2.0)* 96.5 (2.5) 94.7 (3.6)*
Chronic bronchitis 12.6* 17.8 28.2*
Short acting beta-agonist use 12.0* 28.1 65.7*
Long acting beta-agonist use 4.4* 13.3 49.1*
Inhaled corticosteroid use 5.5* 16.4 51.2*
Oral corticosteroid use 0.5* 2 5.9*
Congestive heart failure 1.3* 4.6 5.4
Coronary artery disease 7.5* 13.5 16.5*
Diabetes mellitus 11.6* 21.6 13.1*
Hypertension 36.3* 49.1 50.6
Hyperlipidemia 34.3* 42.5 41.4
History of blood clot 2.8* 5.2 5.7
Peripheral vascular disease 1.3* 2.7 3.4
History of stroke 1.6* 3.5 3.6
Gastrointestinal reflux disease 20.3* 25.9 30.3*
History of compression fracture 3.4* 5.4 6.2
Currently employed 37.3* 28.9 25.3*
Physician-diagnosed asthma 11.4* 21.1 24.6*
Data are presented as mean (standard deviation) or percent. Preserved Ratio Impaired Spirometry (PRISm) defined as: FEV1/FVC ≥ 0.7 & FEV1 < 80% predicted.
Control subjects defined as: FEV1/FVC ≥ 0.7 & FEV1 ≥ 80% predicted. Chronic Obstructive Pulmonary Disease (COPD) subjects defined as: FEV1/FVC < 0.7 &
FEV1 < 80% predicted.
*Denotes univariate p-value < 0.05 when compared to PRISm subjects.
†Bronchodilator responsiveness considered present if the change in FEV1 or FVC was >200 mL and ≥ 12% predicted following administration of short acting
inhaled beta-agonist.
‡MMRC =modified Medical Research Council.
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significantly increased rates of respiratory medication use
relative to smoking controls. However, within the PRISmcohort, the correlation between respiratory medication
use and a history of physician-diagnosed asthma or
evidence of bronchodilator responsiveness (BDR) on
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simple kappa correlation between BDR and respiratory
medication use ranged from 0.06 to 0.12. Thus, the
majority of PRISm subjects with evidence of BDR do
not report use of short- or long-acting beta agonists or
inhaled steroids.
Because controversy regarding the use of fixed thresh-
olds to define respiratory impairment exists, we repeated
the above analyses using lower limit of normal criteria to
define the PRISm, control, and COPD groups. The
prevalence of lower limit of normal-defined PRISm
(LLN-PRISm) is 10.6% (n = 1,082) of the final cohort;
characteristics of these subjects relative to LLN – con-
trol and LLN – COPD subjects are summarized in
Additional file 1: Table S2. LLN-PRISm subjects con-
tinue to demonstrate the highest mean BMI and lowest
mean TLC% predicted, as well as the highest prevalence
of diabetes mellitus; however, the enrichment of female
subjects is no longer present.
The overlap between fixed threshold-defined PRISm
and LLN-PRISm is illustrated in Additional file 1: Figure
S2; 883 subjects are consistently identified as PRISm by
both criteria (simple kappa coefficient = 0.72). Subjects
with PRISm by LLN criteria only (n = 199) are signifi-
cantly older, have increased emphysema and gas trap-
ping as well as a lower FEV1/FVC ratio relative to
subjects identified as having PRISm by both fixed thresh-
old and LLN criteria; 94.5% of these subjects (n = 188)Table 2 Significant predictors of Preserved Ratio Impaired Sp
fixed threshold-defined and (b) lower limit of normal (LLN)-d
Panel (a) – significant predictors in fixed threshold- defined cohorts
Predictor OR [95% CI]
Pack-years 1.008 [1.005-1.012]
Resting oxygen saturation 0.907 [0.875-0.940]
6 minute walk distance (per 100 feet) 0.948 [0.926-0.971]
MMRC Dyspnea score 1.226 [1.153-1.304]
Percent emphysema 1.055 [1.020-1.091]
Total lung capacity% predicted 0.949 [0.943-0.955]
Segmental wall area percent 1.203 [1.168-1.238]
Peripheral vascular disease 1.777 [1.038-3.043]
Physician-diagnosed asthma 1.391 [1.126-1.718]
Age 1.025 [1.014-1.035]
Sex (male) 0.705 [0.598-0.833]
Hyperlipidemia 1.216 [1.031-1.433]
Variables tested but not retained in the final models:
Panel (a): body mass index, Pi10, current smoking, chronic bronchitis, bronchodilato
hypertension, history of blood clots, stroke, gastro-esophageal reflux disease, comp
Panel (b): age, Pi10, chronic bronchitis, bronchodilator responsiveness, congestive
gastro-esophageal reflux disease, compression fractures, and current employme
No significant confounders (defined as causing >10% change in effect estimate) wehave Stage 2 COPD by Global Initiative for Obstructive
Lung Disease (GOLD)11 criteria. Of the subjects who have
PRISm by fixed threshold criteria only (n = 374), 93.9%
(n = 351) of these subjects are considered control sub-
jects using LLN criteria. The reclassification of PRISm
subjects by fixed-threshold and LLN-criteria is illus-
trated in Additional file 1: Figure S3.
Significant epidemiological predictors of PRISm status
relative to control subjects in multivariate models for
both fixed threshold and LLN-defined cohorts are pre-
sented in Table 2; none of the non-significant candidate
independent variables were found to be confounders.
The majority of risk factors identified were consistent re-
gardless of whether fixed threshold or LLN criteria were
used to define PRISm and control status and included
increased cumulative pack-years, lower resting oxygen
saturation, reduced 6-minute walk distance, increased
MMRC dyspnea score, increased percent emphysema
(after adjusting for TLC), decreased total lung capacity%
predicted, increased segmental wall area percentage, and
an increased prevalence of a history of peripheral vascu-
lar disease and physician-diagnosed asthma. Increased
BMI and a history of diabetes mellitus were significant
predictors only in the LLN cohort while female gender
and increased age were significant only in the fixed
threshold-defined cohort.
Multivariate models of PRISm status relative to both
fixed-threshold and LLN-defined COPD are summarizedirometry (PRISm) status relative to control subjects in (a)
efined cohorts in multivariate models
Panel (b) – significant predictors in LLN defined cohorts
Predictor OR [95% CI]
Pack-years 1.008 [1.004-1.012]
Resting oxygen saturation 0.931 [0.897-0.966]
6 minute walk distance (per 100 feet) 0.953 [0.929-0.977]
MMRC Dyspnea score 1.192 [1.116-1.273]
Percent emphysema 1.061 [1.029-1.094]
Total lung capacity% predicted 0.948 [0.942-0.954]
Segmental wall area percent 1.190 [1.154-1.227]
Peripheral vascular disease 2.038 [1.254-3.314]
Physician-diagnosed asthma 1.485 [1.193-1.848]
Diabetes Mellitus 1.372 [1.111-1.695]
African American race 0.266 [0.216-0.328]
Body mass index 1.026 [1.012-1.040]
Current smoking 1.620 [1.337-1.962]
Coronary artery disease 1.370 [1.002-1.874]
r responsiveness, congestive heart failure, coronary artery disease, diabetes,
ression fractures, and current employment.
heart failure, hypertension, hyperlipidemia, history of blood clots, stroke,
nt.
re found.
Wan et al. Respiratory Research 2014, 15:89 Page 6 of 13
http://respiratory-research.com/content/15/1/89in Additional file 1: Table S3. Analogous to the compari-
son of PRISm and control subjects, the majority of pre-
dictors identified on multivariate modeling of PRISm vs.
COPD subjects were consistent regardless of whether
fixed-threshold or LLN criteria were used. Increased
BMI relative to COPD subjects was consistently identi-
fied as a predictor of PRISm status, as was decreased
bronchodilator responsiveness. Radiographic differences,
such as decreased measurements of emphysema, gas
trapping, TLC, and segmental wall area thickness were
also among the robustly identified predictors of PRISm
relative to COPD subjects.
Aim 2: Genetic associations between common genetic
variants and PRISm status
During quality control of the genome-wide SNP geno-
typing data, six Klinefelter syndrome (47XXY) subjects
were identified (Additional file 1: Figure S4). Five of the
six Klinefelter subjects met criteria for PRISm by fixed
threshold criteria while 3 met criteria for PRISm by LLN
standards. This represents a significant enrichment of
PRISm among Klinefelter syndrome subjects regardless of
whether fixed threshold or LLN criteria were applied
(Fisher’s exact p-values 1.53 x 10−4 and 0.02, respectively).
We performed a genome-wide association study (GWAS)
of PRISm status relative to control subjects; results for the
analysis in fixed threshold-defined cohorts are illustrated in
Additional file 1: Figure S5. Although no genetic variant
met the genome-wide threshold for significance (p-value <
5 x 10−8) in either the fixed threshold (Additional file 1:
Table S4) or LLN – defined analyses (Additional file 1:
Table S5), several SNPs with suggestive p-values were iden-
tified within the pleckstrin homology domain containing,
family A member 5 (PLEKHA5) gene as well as within the
voltage-dependent L-type calcium channel subunit beta-2
(CACNB2) gene. The most highly associated SNP from
the fixed-threshold analysis (rs113840005 in PLEKHA5)
was among the top 10 variants identified in the LLN-
analysis. Considerable heterogeneity, as illustrated in
the 10th – 90th percentile values for selected variables
(Additional file 1: Table S6), exists among PRISm sub-
jects and may contribute to the lack of genetic signal
in GWAS analysis.
Aim 3: Unsupervised cluster analysis to identify potential
subgroups within PRISm subjects
The subset of fixed threshold-defined PRISm subjects
with complete data included in the k-means clustering
analysis (n = 1,135) did not differ from the full cohort of
PRISm subjects with respect to mean age, pack-years,
BMI, or distribution by gender or current smoking status.
Normalized mutual information (NMI) analysis using a
five-fold cross-validation strategy demonstrated high clus-
ter reproducibility for k = 3 clusters (Additional file 1:Table S7). An overview of the analysis is shown qualita-
tively in Figure 2 while the specific results of unsupervised
k-means clustering in non-Hispanic white and African
American PRISm subjects are illustrated in Figures 3
and 4, respectively. Clusters observed in NHW were
reasonably reproducible in the AA, as illustrated in
Additional file 1: Figure S6. Subgroup characteristics
by cluster are summarized in Table 3. Members of
Cluster 1 demonstrate the highest FEV1/FVC ratio and
forced expiratory flow rate at 25%-75% of FVC (FEF25–75),
as well as the lowest mean emphysema and gas trapping;
we refer to this cluster as a putative “PRISm – Restricted
cluster”. Members of Cluster 2 have the lowest mean BMI
and FEV1/FVC ratio, as well as the highest mean emphy-
sema and gas trapping; we refer to this cluster as the
“PRISm – COPD cluster”. Finally, members of Cluster 3
have the highest mean BMI, the greatest degree of impair-
ment in FEV1% predicted, the thickest segmental wall
area, the lowest FEF25–75 flow rates, and the highest preva-
lence of diabetes mellitus and rates of bronchodilator
responsiveness (BDR); we refer to this cluster as the
“PRISm – Metabolic cluster”. Members of the Cluster
3 also demonstrate the highest mean MMRC dyspnea
scores and the lowest mean 6 minute walk distance.
We also performed cluster analysis on the LLN-
defined PRISm cohort; the subset of subjects with
complete data (n = 978) did not differ from the full LLN-
PRISm cohort with respect to mean age, pack-years
smoked, BMI, or distribution by gender; there were sig-
nificantly fewer current smokers (60% vs. 70.2%) in the
subset with complete data used for cluster analysis. NMI
and silhouette width analysis demonstrated high cluster re-
producibility for k = 4 clusters (Additional file 1: Table S7).
The results of unsupervised k-means clustering in
NHW and AA subjects are illustrated in Additional file 1:
Figure S7 (panels (a) and (b) respectively). Separation be-
tween clusters in each of these analyses (NHW and AA) is
not as distinct as in the fixed threshold analysis; addition-
ally, the clusters found in NHW did not appear to overlap
well with clusters identified in the AA analysis (Additional
file 1: Figure S8). Characteristics of each cluster are
summarized in Additional file 1: Table S9. We have
putatively assigned Clusters 1, 2, and 3 to be analogous
to the “PRISm-restrictive”, “PRISm-COPD”, and “PRISm-
metabolic” subtypes described in the fixed-threshold ana-
lysis. Members of Cluster 4 have the highest rates of
current smoking; however, beyond that, the clusters ap-
pear to represent relatively distinct subgroups in NHW
and AA subjects. In the NHW LLN-PRISm Cluster 4, sub-
jects have the lowest BMI and highest resting oxygen sat-
uration and best exercise capacity while Cluster 4 subjects
in the AA LLN-PRISm analysis appear to be more ill with
the greatest impairment in FEV1% predicted, increased
segmental wall area thickness and decreased FEF25–75.
Figure 2 Overview of cluster analysis in subjects with Preserved Ratio Impaired Spirometry (PRISm).
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COPD, interstitial lung disease, and metabolic pheno-
types were examined for associations with the clusters
identified in the fixed-threshold analysis (Additional
file 1: Table S10). The minor (risk) allele frequency of
rs8050136, located in the first intron of the fat mass
and obesity associated (FTO) gene, by subgroup is il-
lustrated in Additional file 1: Figure S9; a relative en-
richment of risk alleles in the PRISm – Metabolic
subgroup was noted among African American subjects
(ANOVA p-value 0.05), however, this enrichment was
not statistically significant among non-Hispanic white
subjects.
Discussion
In this manuscript, we examine detailed demographic,
spirometric, and radiographic features of subjects with
Preserved Ratio Impaired Spirometry and leverage these
data to explore genetic associations and subgroups
within the cohort. We confirm the overall prevalence of
PRISm within current and former smokers in our cohortis consistent with the prevalence reported in other cross-
sectional studies, including several population-based
studies [10–13,15,31]. We affirm previously reported
associations with body mass index and diabetes melli-
tus and report novel associations with radiographic
and functional predictors of PRISm status (Aim 1).
While no genome-wide significant genetic predictors
were identified in our GWAS studies, we uncovered a
novel association between PRISm and Klinefelter’s syn-
drome (Aim 2). Finally, the results of unsupervised
clustering analysis demonstrate 3 clusters which may
represent pathobiologically distinct subgroups within
the PRISm cohort.
Aim 1: Epidemiology of PRISm
As with obstructive lung diseases, controversy regarding
the delineation between normal and abnormal exists for
PRISm. Differences in the populations defined by fixed
threshold (i.e. GOLD criteria) versus lower limit of nor-
mal FEV1 criteria likely contribute to differences in associ-
ations with certain epidemiological predictors identified in
Figure 3 Results of k-means clustering in fixed-threshold defined Preserved Ratio Impaired Spirometry (PRISm) in non-Hispanic whites.
Legend: Unsupervised k-means clustering was performed in non-Hispanic white subjects with PRISm. The first two principal components generated
using the scaled 6 key input variables used for clustering (body mass index, FEV1%, predicted, FEV1/FVC ratio, percent emphysema, total lung capacity,
and segmental wall area) are plotted on the x- and y-axes respectively.
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Americans in the LLN-defined PRISm cohort may reflect
less accurate population-based prediction equations for or
increased variability in African Americans rather than a
distinct pathobiological process.
Despite the lack of a consensus definition for PRISm,
the majority of associations reported in our study were re-
markably consistent regardless of whether fixed (GOLD)
or LLN criteria were utilized. Previously reported associa-
tions with increased mean BMI and a high prevalence
of comorbid conditions such as diabetes mellitus
[6,9,10,12,13,15,18] were observed in our cohort on
univariate analyses. We additionally confirm associa-
tions with decreased total lung capacity and decreased
emphysema first reported in our analysis of PRISm
subjects among the first 2500 subjects recruited in
COPDGene [8].
In multivariable models, PRISm subjects had increased
cumulative exposure to tobacco smoke as well as an in-
creased prevalence of physician-diagnosed asthma and
peripheral vascular disease relative to control subjects.
These factors may contribute to the increase in symptomsas assessed through the MMRC score, decreased exercise
tolerance, and decreased resting oxygen saturation also
observed in this cohort relative to control subjects. In
multivariate models comparing PRISm with COPD sub-
jects, increased body mass index and an increased preva-
lence of diabetes mellitus were consistently identified as
predictors; whether these factors are pathobiologically re-
lated to the development of these two distinct disease
states is a topic that warrants investigation in the future.
Radiographic variables, such as percent emphysema and
TLC, were among the most consistently identified predic-
tors of PRISm status in multivariate models relative to
both control and COPD subjects.
The role of increased BMI among PRISm subjects
continues to deserve special consideration. Although
obesity has been associated with proportionate decreases
in FEV1 and FVC as well as decreases in TLC, lung
function values of obese subjects typically remain within
the normal range [32]; thus the degree of impairment in
lung function in PRISm subjects is unlikely to be due
solely to the mechanical properties of increased body
mass. This supposition is supported by the divergent
Figure 4 Results of k-means clustering in fixed-threshold defined Preserved Ratio Impaired Spirometry (PRISm) in African Americans.
Legend: Unsupervised k-means clustering was performed in African American subjects with PRISm. The first two principal components generated
using the scaled 6 key input variables used for clustering (body mass index, FEV1%, predicted, FEV1/FVC ratio, percent emphysema, total lung
capacity, and segmental wall area) are plotted on the x- and y-axes respectively.
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tive to PRISm over the last half century (Additional file 1:
Figure S10); the dramatic increase in the prevalence of
overweight and obesity [33] is not reflected in the relatively
stable prevalence of PRISm [7–9,11–13,15,16,22,31,34].
Aim 2: Genetic associations
The association between Klinefelter’s syndrome and
PRISm is consistent with previous reports of an in-
creased prevalence of restriction [35–37] in this population;
in fact, all six Klinefelter subjects identified demonstrated a
TLCCT < 80% predicted (data not shown). We acknowledge
the limitations associated with the use of male prediction
equations for lung function in this subgroup, as traditional
formulas do not account for the eunuchoid proportions
which characterize this syndrome. However, given previous
reports of decreased lung compliance [36], an increased
prevalence of respiratory symptoms [38,39], and increased
mortality due to respiratory causes among Klinefelter’s sub-
jects [40,41], we believe the association may be indicative
of true pathobiological differences and warrants additional
investigation in the future.Although no single genetic variant met the accepted
genome-wide threshold for significance, we identified
suggestive associations between PRISm and variants
within the PLEKHA5 and CACNB2 genes. rs113840005,
which was a top variant in both the fixed threshold and
LLN analyses, is located within an intron of the PLEKHA5
gene. Multiple splice variants of this gene have been iden-
tified; some isoforms are ubiquitously expressed while
other isoforms are highly specific to tissue type and devel-
opmental stage. In general, the protein products of the
PLEKHA5 gene are typically located in the cytosol of cells
and are believed to contribute to intracellular signaling
and cytoskeletal organization [42]; the mechanism by
which variants in this gene are associated with PRISm is
unclear. Intronic variants within the CACNB2 gene were
among the most strongly associated in the fixed-threshold
analysis. Analogous to PLEKHA5, multiple isoforms of the
protein product exist. Variants within this gene have been
associated with blood pressure levels and hypertension
[43,44] as well as Brugada syndrome [45–47]. Additional
investigations into the mechanism behind the association
of variants at this locus with PRISm are warranted.
Table 3 Results of unsupervised k-means clustering in (a) non-Hispanic white and (b) African American subjects with
fixed threshold-defined Preserved Ratio Impaired Spirometry (PRISm)
(a) Non-Hispanic White subjects (b) African American subjects
Feature Cluster 1 Cluster 2 Cluster 3 Cluster 1 Cluster 2 Cluster 3
n 227 291 137 171 167 142
Age 57.9 (8.2) 62.2 (8.1) 59.2 (9.4) 52.9 (5.8) 54.6 (6.1) 52.6 (5.3)
Sex (% male) 34.8 45.7 51.1 47.4 56.9 45.1
Body Mass Index 30.9 (6.4) 30.4 (6.3) 36.2 (7.1) 32.0 (6.8) 27.3 (6.0) 35.7 (8.4)
Current smoker 53.3 43.6 49.6 84.8 83.8 80.3
Pack-years 42.8 (22.6) 46.6 (24.5) 50.9 (29.7) 35.6 (18.5) 39.6 (24.0) 38.1 (21.4)
FEV1% predicted 74.2 (4.3) 73.4 (5.3) 60.5 (7.8) 73.3 (5.1) 72.7 (6.2) 62.5 (8.9)
FEV1/FVC 0.80 (0.04) 0.74 (0.03) 0.74 (0.04) 0.83 (0.04) 0.74 (0.03) 0.75 (0.03)
FEF 25–75 2.21 (0.65) 1.58 (0.47) 1.41 (0.47) 2.38 (0.71) 1.58 (0.50) 1.42 (0.43)
Resting O2 saturation 96.4(2.3) 96.3 (2.1) 95.2 (2.9) 97.1 (2.2) 97.1 (2.3) 96.6 (2.7)
TLCCT
* % predicted 79.4 (9.8) 90.4 (10.7) 74.4 (12.7) 71.0 (11.1) 83.6 (12.3) 71.6 (12.3)
Percent emphysema 0.6 (0.7) 2.6 (2.7) 0.9 (1.1) 0.5 (0.6) 2.7 (4.5) 0.8 (1.0)
Segmental Wall Area% 62.0 (2.5) 60.6 (2.3) 64.7 (2.6) 62.4 (2.8) 61.9 (2.9) 65.7 (2.5)
Percent Gas Trapping 6.5 (6.0) 13.5 (8.6) 9.8 (7.1) 7.2 (7.3) 14.8 (13.5) 9.4 (7.5)
Diabetes Mellitus 18.5 14.4 36.5 22.8 15.6 27.5
Hypertension 36.6 47.4 56.2 53.8 51.5 54.2
Hyperlipidemia 45.4 58.8 59.9 31.0 24.0 29.6
Chronic bronchitis 16.3 15.8 32.9 11.1 19.2 14.8
Bronchodilator Response† 11.5 13.5 22.2 11.4 9.2 20.1
MMRC‡ 1.154 (1.32) 1.13 (1.29) 1.95 (1.50) 1.63 (1.53) 1.57 (1.47) 1.96 (1.53)
6 minute walk distance 1386.5 (347.1) 1392.2 (320.4) 1132.6 (390.2) 1219.9 (349.4) 1279.5 (338.1) 1099.2 (342.1)
Results are reported as mean (SD) or percent.
Preserved Ratio Impaired Spirometry (PRISm) defined as: FEV1/FVC ≥ 0.7 & FEV1 < 80% predicted.
*TLCCT = Total Lung Capacity by computed tomography.
†Bronchodilator response considered present if the change in FEV1 or FVC was >200 mL and ≥ 12% predicted following administration of short acting
inhaled beta-agonist.
‡MMRC =Modified Medical Research Council.
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Clinical management strategies for PRISm are poorly de-
fined and reflect the low specificity of spirometric mea-
surements alone in identifying distinct disease processes
in this cohort [13,14]. Overt and subclinical interstitial
lung disease [5], chest wall abnormalities, neuromuscular
and functional impairments, as well as airway diseases
(such as asthma and chronic obstructive pulmonary dis-
ease) which have classically been associated with ob-
struction [6,9,48], can all produce the PRISm pattern on
spirometry; what remains unknown is the proportion at-
tributable to each process and how to identify different
groups of subjects. When we incorporated key clinical
and radiographic variables with existing spirometric data
into an unbiased clustering algorithm, we were able to
identify clinically relevant subtypes within the PRISm
cohort.
Previous studies have supported the existence of an
airway disease/COPD subgroup among PRISm subjects
[6,9]; we were likewise able to identify a putative COPDsubgroup (Cluster 2 in both the NHW and AA analyses)
with evidence of relatively increased emphysema and gas
trapping, preserved TLC, and a relatively reduced FEV1/
FVC ratio. Interestingly, this group appears to have the
lowest degree of physiological impairment; they experi-
ence the least dyspnea (as assessed by MMRC score),
have the best exercise capacity (highest 6MWD), and the
least hypoxemia. In a longitudinal study by Guerra et al.
[9], approximately one-third of subjects with PRISm even-
tually developed airflow obstruction on spirometry –
Cluster 2 may be enriched for subjects with “early COPD”
who have not yet developed the classical obstructive pat-
tern. Longitudinal data, which is currently being collected
in the COPDGene cohort, will be crucial to investigating
this hypothesis.
The PRISm-metabolic subgroup represents a highly
symptomatic and functionally limited group for whom
treatment options have not been systematically explored.
This subgroup has the greatest degree of spirometric im-
pairment in FEV1 which may be related to the increased
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ings, as well as the high prevalence of bronchodilator re-
sponsiveness in this subgroup, the benefit of inhaled
steroids and/or bronchodilators in this subgroup pre-
sents a clinically relevant question for future studies.
In summary, we have analyzed the epidemiological
and radiographic predictors, explored clinically relevant
putative subgroups, and identified a novel association
with Klinefelter’s syndrome in PRISm. The strengths of
the current study include the utilization of a large cohort
with rich data in multiple domains as well as the appli-
cation of rigorous, unbiased interrogations to both
characterize and subtype this relatively understudied
syndrome. Despite this, we acknowledge the following
limitations. First, the lack of visual assessments of CT
data for the majority of the cohort limits our ability to
ascertain the impact of chest wall or diaphragmatic ab-
normalities and atypical interstitial/parenchymal infil-
trates among the PRISm cohort. Second, although this
cohort is the largest to date with genetic data available,
the number of subjects is modest in the context of
genome-wide association studies and limits our power
to detect variants of modest effect sizes. Lastly, the de-
gree to which the findings reported in our study are
generalizable to other populations, such as non-smokers
and subjects outside of the United States, should be ex-
plored. Future work in independent populations of PRISm
subjects, as well as in vivo and in vitro work in model sys-
tems, to explore the biological mechanisms behind the as-
sociations reported in our manuscript are warranted.
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